This document is intended to serve as a guide to aid in the interpretation of tests for the diagnosis of Toxoplasma infection.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in clinical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Process document.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For further information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org
Clinical Use and Interpretation of Serologic Tests for *Toxoplasma gondii*; Approved Guideline

Volume 24 Number 6

Lynne S. Garcia, M.S., F(AAM), Chairholder
Thomas R. Fritsche, Ph.D., M.D.
Katharine K. Grady, M.T.(ASCP), M.M.Sc.
George R. Healy, Ph.D.
James McAuley, M.D.
Andy Rocha
Marianna Wilson, M.S.
Johnson Wong

Abstract

CLSI document M36-A—*Clinical Use and Interpretation of Serologic Tests for Toxoplasma gondii; Approved Guideline* is intended to aid laboratorians and physicians in determining the status of patients potentially infected with *Toxoplasma gondii*. Because *Toxoplasma* organisms are rarely detected in humans infected with the parasites, immunodiagnostic methods are used to indicate the presence of the infection by detecting *Toxoplasma*-specific antibodies or parasite material in body fluids. Clinical toxoplasmosis can be categorized into four groups: 1) acquired in the immunocompetent patient; 2) acquired or reactivated in the immunodeficient patient; 3) ocular; and 4) congenital. Methods of diagnosis and their interpretations differ for each clinical category. This guideline summarizes the current methods of choice to diagnose toxoplasmosis and discusses the challenges associated with serologic testing for *Toxoplasma*.


The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at www.clsi.org. If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: customerservice@clsi.org; Website: www.clsi.org.
Copyright ©2004 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to permissions@clsi.org.

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail permissions@clsi.org.

Suggested Citation


Proposed Guideline

October 2002

Approved Guideline

February 2004

ISSN 0273-3099
# Contents

Abstract .................................................................................................................................................... i  
Committee Membership ........................................................................................................................ iii  
Foreword .............................................................................................................................................. vii  

1 Scope .......................................................................................................................................... 1  

2 Introduction ................................................................................................................................ 1  

3 Definitions .................................................................................................................................. 1  

4 Background ................................................................................................................................ 1  
   4.1 Life Cycle ............................................................................................................................ 1  
   4.2 Epidemiology...................................................................................................................... 2  
   4.3 Clinical Conditions ........................................................................................................ 2  

5 Methods of Diagnosis ....................................................................................................................... 3  
   5.1 Parasite Identification ..................................................................................................... 3  
   5.2 Molecular Detection ...................................................................................................... 4  
   5.3 Antibody Detection ........................................................................................................ 4  
   5.4 Antigen Detection .......................................................................................................... 7  

6 Safety Precautions ............................................................................................................................ 7  

7 Specimen Collection and Handling ................................................................................................ 8  

8 Clinical Use of Immunodiagnostic Tests ......................................................................................... 8  
   8.1 Determination of Antibody Status ................................................................................ 8  
   8.2 Diagnosis of Acute Acquired Infections .................................................................. 9  
   8.3 Diagnosis of Congenital Infection ............................................................................. 11  
   8.4 Diagnosis in the Newborn .......................................................................................... 12  
   8.5 Diagnosis of Ocular Infection .................................................................................... 13  
   8.6 Diagnosis in the Immunocompromised Host ........................................................... 13  
   8.7 General Interpretation of Test Results ...................................................................... 14  

9 Challenges Associated with Immunodiagnostic Testing ............................................................... 14  
   9.1 Commercial Kits .......................................................................................................... 14  
   9.2 Choosing Tests .............................................................................................................. 15  
   9.3 Nonstandardized Use of Tests ................................................................................... 15  
   9.4 Nonstandardized Reporting of Results ..................................................................... 15  
   9.5 False-Positive Reactions ............................................................................................. 16  
   9.6 Quality Assurance/Quality Control ......................................................................... 16  
   9.7 Reference Laboratories ............................................................................................... 16  

References ............................................................................................................................................. 17  

Summary of Comments and Subcommittee Responses ...................................................................... 18  

The Quality System Approach ......................................................................................................... 20  

Related NCCLS Publications ......................................................................................................... 21
Foreword

The purpose of this project is to update and inform laboratory scientists and physicians concerning the appropriate selection, performance, and interpretation of *T. gondii* serodiagnostic tests. This educational effort addresses the serology of *T. gondii*, with particular attention to optimal serum collection times and follow-up testing, performance characteristics, interpretation of results, limitations of testing, and types of available tests.

This guideline is needed, because there currently exists a great deal of potential for misapplication and misinterpretation of *T. gondii* serodiagnostic tests, i.e., interpretation of results for different patient populations, variability of test result reporting, and lack of mandatory expression of test results. The clinician is presented with the problem of determining if an infection is newly acquired, reactivated, or chronic. The laboratorian is faced with choosing tests from an array of commercially available kits for IgG and IgM antibody detection. In the absence of a fairly sophisticated knowledge of the subtleties of *Toxoplasma* serology, there exists a dangerous potential for the misuse, misapplication, and general misunderstanding of test results.

This guideline is intended for clinical laboratory scientists, clinicians, and manufacturers involved in the diagnosis of toxoplasmosis.

Key Words

Antibody detection, antigen detection, avidity, congenital toxoplasmosis, diagnosis, EIA, IFA, IgA, IgE, IgG, IgM, PCR, serodiagnosis, *Toxoplasma* diagnostic products, *Toxoplasma gondii*, toxoplasmosis
Clinical Use and Interpretation of Serologic Tests for *Toxoplasma gondii*; Approved Guideline

1 Scope

This guideline provides the user with information about the biology of *Toxoplasma gondii*; the methods available for use in the laboratory diagnosis of human toxoplasmosis; the techniques that should be performed for specific clinical situations; the interpretation of the laboratory results; and the problems inherent in these methods.

2 Introduction

Individuals infected with the protozoan parasite, *Toxoplasma gondii*, generally show no detectable signs of infection and require no treatment. A small percentage of patients may require treatment, i.e., those with CNS toxoplasmosis or active ocular disease. However, if a woman becomes infected during pregnancy and the infection is passed to the fetus, the fetus may be catastrophically affected. These effects may be minimized or averted if *Toxoplasma* infection is diagnosed in a timely fashion and therapy instituted.

The diagnosis of toxoplasmosis generally relies on the detection of *Toxoplasma*-specific antibodies. Many laboratorians and clinicians are not familiar with the available diagnostic tools, because toxoplasmosis is not generally considered by most physicians to be a serious infection in persons with normal immune function. However, detection of primary infection in a pregnant woman with appropriate patient management is important to minimize the potential severe effects on the fetus. Also, knowledge of an individual’s antibody status is necessary for clinical management if the patient is immunosuppressed or has lymphadenopathy. There are a variety of commercially available kits for the detection of *Toxoplasma* antibodies with a multitude of sensitivity and specificity rates, creating a wide range of choices for laboratorians. Even assuming that the test results obtained are valid, correct interpretation of the results may be problematic due to lack of knowledge by laboratorians and clinicians.

3 Definitions

*Immunoglobulin class/*Immunoglobulin isotype – A classification of immunoglobins based on antigenic and structural differences of the heavy (H) chain; **NOTE:** There are five classes: IgG, IgA, IgM, IgD, and IgE.

4 Background

4.1 Life Cycle

*Toxoplasma gondii* is a protozoan parasite that infects most species of warm-blooded animals, including humans. Members of the cat family (Felidae) are the only known definitive hosts for the sexual stages of *T. gondii* and thus are the main reservoirs of infection. The three stages of this obligate intracellular parasite are:

1) tachyzoites, which rapidly proliferate and destroy infected cells during acute infection;
2) bradyzoites, which slowly multiply in tissue cysts; and
3) sporozoites in oocysts.
Tachyzoites and bradyzoites occur in body tissues; oocysts are excreted in cat feces. After tissue cysts or oocysts are ingested by the cat, viable organisms are released and invade epithelial cells of the small intestine where they undergo an asexual cycle followed by a sexual cycle with the production of oocysts, which are then excreted. The unsporulated (i.e., uninfected) oocyst takes one to five days after excretion to become sporulated (infective). Although cats shed oocysts for only one to two weeks, large numbers may be shed, often exceeding 100,000 per gram of feces.\(^1\) Oocysts can survive in the environment for several months or longer and are remarkably resistant to disinfectants, freezing, and drying, but are killed by heating to 70 °C for 10 minutes. Cats become infected with \(T. gondii\) by carnivorism. Therefore, feral cats and domestic cats that are allowed to roam outside are much more likely to become infected than domestic cats that are confined indoors and fed only commercially prepared cat food.

Human infection may be acquired in several ways:

- ingestion of undercooked, infected meat containing \(Toxoplasma\) cysts;
- ingestion of the oocyst from fecally contaminated hands, food, and water;
- organ transplantation or blood transfusion;
- transplacental transmission; and
- accidental inoculation of tachyzoites.

The two major routes of transmission of \(Toxoplasma\) to humans are oral and congenital.\(^2\) Risk behaviors include eating undercooked, infected meat or eating food that has been cross-contaminated with undercooked, infected meat; working outside in the dirt (gardening, yard work); changing the cat litter box; drinking contaminated water; and eating unwashed fruits and vegetables.\(^3\) In humans, ingesting either the tissue cyst or the oocyst results in the rupture of the cyst wall, releasing organisms that invade the intestinal epithelium, disseminate throughout the body via blood cells, and multiply intracellularly. The host cell dies and releases the tachyzoites, which invade adjacent cells and continue the process. The tachyzoites transform into bradyzoites and form tissue cysts; most commonly in skeletal muscle, myocardium, and brain; these cysts may remain throughout the life of the host. Recrudescence of clinical disease may occur if the host becomes immunosuppressed.

### 4.2 Epidemiology

Serologic prevalence data indicate that toxoplasmosis is one of the most common infections of humans throughout the world. The prevalence of positive serologic titers increases with age. Infection is more common in warm climates and at lower altitudes than in cold climates and mountainous regions. This distribution is probably related to conditions favoring sporulation and survival of oocysts. Variations in the prevalence of infection between geographic areas and between population groups within the same locale are also probably due to differences in exposure.\(^4\) High prevalence of infection in France has been related to a preference for eating raw or undercooked meat. However, high prevalence in Central America has been related to the frequency of stray cats in a climate favoring survival of oocysts. In the United States in 1967, prevalence rates of up to 30% were found along the seacoast, with rates of less than 1% in the Rocky Mountains and the desert Southwest. More recent data comparing antibody prevalence in U.S. military recruits in 1962 and 1989 indicated a one-third decrease in seropositivity. The overall seroprevalence in the United States as determined with specimens collected by the third National Health and Nutrition Examination Survey (NHANES III) between 1988 and 1994 was found to be 22.5%, with seroprevalence among women of childbearing age (15 to 45 years) of 15%.\(^5\)

### 4.3 Clinical Conditions

Toxoplasmosis can be clinically categorized into four groups of patients:

1) acquired in the immunocompetent patient;
2) acquired or reactivated in the immunosuppressed or immunodeficient patient;
The Quality System Approach

NCCLS subscribes to a quality system approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents through a gap analysis. The approach is based on the model presented in the most current edition of NCCLS HS1—A Quality System Model for Health Care. The quality system approach applies a core set of “quality system essentials (QSEs),” basic to any organization, to all operations in any healthcare service’s path of workflow. The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The quality system essentials (QSEs) are:

- Documents & Records
- Organization
- Personnel
- Equipment
- Purchasing & Inventory
- Information Management
- Process Improvement
- Occurrence Management
- Assessment
- Service & Satisfaction
- Facilities & Safety

M36-A addresses the quality system essentials (QSEs) indicated by an “X.” For a description of the other NCCLS documents listed in the grid, please refer to the Related NCCLS Publications section on the next page.

<table>
<thead>
<tr>
<th>Documents &amp; Records</th>
<th>Organization</th>
<th>Personnel</th>
<th>Equipment</th>
<th>Purchasing &amp; Inventory</th>
<th>Process Control</th>
<th>Information Management</th>
<th>Occurrence Management</th>
<th>Assessment</th>
<th>Process Improvement</th>
<th>Service &amp; Satisfaction</th>
<th>Facilities &amp; Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>GP29</td>
<td>M29</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from NCCLS document HS1—A Quality System Model for Health Care.

Path of Workflow

A path of workflow is the description of the necessary steps to deliver the particular product or service that the organization or entity provides. For example, GP26-A2 defines a clinical laboratory path of workflow which consists of three sequential processes: preanalytical, analytical, and postanalytical. All clinical laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

M36-A addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other NCCLS documents listed in the grid, please refer to the Related NCCLS Publications section on the next page.

<table>
<thead>
<tr>
<th>Preanalytic</th>
<th>Analytic</th>
<th>Postanalytic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient Assessment</td>
<td>Specimen Collection</td>
<td>Specimen Transport</td>
</tr>
<tr>
<td>X</td>
<td>X</td>
<td>H18</td>
</tr>
<tr>
<td>H4</td>
<td>H4</td>
<td>H18</td>
</tr>
<tr>
<td>I/LA18</td>
<td>H18</td>
<td>M15</td>
</tr>
<tr>
<td>I/LA21</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Adapted from NCCLS document HS1—A Quality System Model for Health Care.
Related NCCLS Publications*

EP9-A2  Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline—Second Edition (2002). This document addresses procedures for determining the bias between two clinical methods or devices, and for the design of a method comparison experiment using split patient samples and data analysis.

EP12-A  User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline (2002). This document contains a protocol that optimizes the experimental design for the evaluation of qualitative tests, to better measure performance and provide a structured data analysis.

GP29-A  Assessment of Laboratory Tests When Proficiency Testing is Not Available; Approved Guideline (2002). This document offers methods to assess test performance when proficiency testing (PT) is not available; these methods include examples with statistical analyses. This document is intended for use by laboratory managers and testing personnel in traditional clinical laboratories as well as in point-of-care and bedside testing environments.

H4-A4  Procedures and Devices for the Collection of Diagnostic Blood Specimens by Skin Puncture; Approved Standard—Fourth Edition (1999). A consolidation of H4-A3 and H14-A2, this standard provides detailed descriptions and explanations of proper collection techniques, as well as hazards to patients from inappropriate specimen collection by skin puncture procedures.

H18-A2  Procedures for the Handling and Processing of Blood Specimens; Approved Guideline—Second Edition (1999). This guideline addresses multiple factors associated with handling and processing specimens, as well as factors that can introduce imprecision or systematic bias into results.

I/LA18-A2 Specifications for Immunological Testing for Infectious Diseases; Approved Guideline—Second Edition (2001). This guideline outlines specimen requirements; performance criteria; algorithms for the potential use of sequential or duplicate testing; recommendations for intermethod comparisons of immunological test kits for detecting infectious diseases; and specifications for development of reference materials.

I/LA21-A Clinical Evaluation of Immunoassays; Approved Guideline (2002). This guideline will offer recommendations on designing trials that are appropriate for evaluating both the safety and effectiveness of immunoassays. It will be a valuable resource in determining the necessary steps in designing an evaluation for new methods, new applications for existing methods, or variations on existing methods.

M15-A Laboratory Diagnosis of Blood-borne Parasitic Diseases; Approved Guideline (2000). This document contains guidelines for specimen collection, blood film preparation, and staining procedures. Recommendations for optimum timing of specimen collection to assist laboratories in detecting, identifying, and reporting certain parasites are also included.

M29-A2 Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline—Second Edition (2002). Based on U.S. regulations, this document provides guidance on the risk of transmission of hepatitis viruses and human immunodeficiency viruses in any laboratory setting; specific precautions for preventing the laboratory transmissions of blood-borne infection from laboratory instruments and materials; and recommendations for the management of blood-borne exposure.

* Proposed- and tentative-level documents are being advanced through the NCCLS consensus process; therefore, readers should refer to the most recent editions.

©Clinical and Laboratory Standards Institute. All rights reserved.
Explore the Latest Offerings from CLSI!

As we continue to set the global standard for quality in laboratory testing, we're adding initiatives to bring even more value to our members and customers.

**Shop Our Online Products**

Including eM100, the interactive searchable database for drug selection, interpretation, and quality control procedures within M100-S23.

**Visit the CLSI U Education Center**

Where we provide the convenient and cost-effective education resources that laboratories need to put CLSI standards into practice, including webinars, workshops, and more.

**Shop Our Online Products**

Including eCLIPSE Ultimate Access™, CLSI's cloud-based, online portal that makes it easy to access our standards and guidelines—anytime, anywhere.

**Find Membership Opportunities**

See the options that make it even easier for your organization to take full advantage of CLSI benefits and our unique membership value.

For more information, visit [www.clsi.org](http://www.clsi.org) today.